Skip to Main Content

Author Details

Vladimir Kirkin
the Institute of Cancer Research London
1992
51
32
PMIDPaper TitleJournal TitlePublished Year
37026591Discovery of an <i>In Vivo</i> Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones.J Med Chem2023
34241570Targeting autophagy in disease: established and new strategies.Autophagy2022
35653645Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 <i>In Vivo</i>.J Med Chem2022
34850536FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.Mol Oncol2022
34795259Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage.Nat Commun2021
30990354An atypical LIR motif within UBA5 (ubiquitin like modifier activating enzyme 5) interacts with GABARAP proteins and mediates membrane localization of UBA5.Autophagy2020
31654670Selective Autophagy Receptors in Neuronal Health and Disease.J Mol Biol2020
31879968Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.Hepatology2020
32882854Atg8-Family Proteins-Structural Features and Molecular Interactions in Autophagy and Beyond.Cells2020
32612269Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.Sci Rep2020
32153400Theranostic Attributes of Acoustic Cluster Therapy and Its Use for Enhancing the Effectiveness of Liposomal Doxorubicin Treatment of Human Triple Negative Breast Cancer in Mice.Front Pharmacol2020
32275432Achieving <i>In Vivo</i> Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders.J Med Chem2020
32228485Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.BMC Cancer2020
32220971Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.Mol Cancer Ther2020
31517566<i>De novo</i> phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy.Autophagy2020
31082435History of the Selective Autophagy Research: How Did It Begin and Where Does It Stand Today?J Mol Biol2020
30353166Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.Oncogene2019
31803049Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice.Front Pharmacol2019
30176150Driving next-generation autophagy researchers towards translation (DRIVE), an international PhD training program on autophagy.Autophagy2019
31585693A Diversity of Selective Autophagy Receptors Determines the Specificity of the Autophagy Pathway.Mol Cell2019
31147600Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.Oncogene2019
28429767Love laughs at Locksmiths: Ubiquitylation of p62 unlocks its autophagy receptor potential.Cell Res2017
28253953Methods for Studying Interactions Between Atg8/LC3/GABARAP and LIR-Containing Proteins.Methods Enzymol2017
28381481FKBP8 recruits LC3A to mediate Parkin-independent mitophagy.EMBO Rep2017
26929408Structural and Functional Analysis of a Novel Interaction Motif within UFM1-activating Enzyme 5 (UBA5) Required for Binding to Ubiquitin-like Proteins and Ufmylation.J Biol Chem2016
26799652Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).Autophagy2016
25839431Caging the elephant: selective autophagy tackles giant intracellular protein crystals.Mol Cell2015
24462201Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy.Mol Cell2014
23043107ATG8 family proteins act as scaffolds for assembly of the ULK complex: sequence requirements for LC3-interacting region (LIR) motifs.J Biol Chem2012
22966490Guidelines for the use and interpretation of assays for monitoring autophagy.Autophagy2012
20971954Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain.Blood2011
21071203Ubiquitin networks in cancer.Curr Opin Genet Dev2011
20010802Nix is a selective autophagy receptor for mitochondrial clearance.EMBO Rep2010
20551902CIN85 regulates dopamine receptor endocytosis and governs behaviour in mice.EMBO J2010
20424122Selective autophagy in cancer development and therapy.Cancer Res2010
19250911A role for NBR1 in autophagosomal degradation of ubiquitinated substrates.Mol Cell2009
19398892NBR1 cooperates with p62 in selective autophagy of ubiquitinated targets.Autophagy2009
19450525A role for ubiquitin in selective autophagy.Mol Cell2009
19502794NBR1 and p62 as cargo receptors for selective autophagy of ubiquitinated targets.Cell Cycle2009
17303403Role of ubiquitin- and Ubl-binding proteins in cell signaling.Curr Opin Cell Biol2007
17557115The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells.Cell Death Differ2007
16282344Fas ligand is localized to membrane rafts, where it displays increased cell death-inducing activity.Blood2006
16320199Hyperforin acts as an angiogenesis inhibitor.Planta Med2005
16204241Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL.J Biol Chem2005
14996506The role of Bcl-2 family members in tumorigenesis.Biochim Biophys Acta2004
15386354MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo.Int J Cancer2004
12566318Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.Cancer Res2003
11850844Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis.Oncogene2002
11596151Markers for the lymphatic endothelium: in search of the holy grail?Microsc Res Tech2001
11683876Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2.Eur J Biochem2001
  • 1 - 50 of 51

Recommended Authors

Alexandre Rosa Campos
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2015
Number of shared co-authors 1
Toshiro Moroishi
Kumamoto University
Career Start Year 2011
Number of shared co-authors 1
Florent Dingli
Institut Curie, PSL Research University
Career Start Year 2011
Number of shared co-authors 0
Evangelos Pazarentzos
University of California san francisco
Career Start Year 2011
Number of shared co-authors 0
Itay Koren
Bar-Ilan University
Career Start Year 2009
Number of shared co-authors 1
Guo Chen
China Pharmaceutical University
Career Start Year 2009
Number of shared co-authors 1
Franziska Kriegenburg
Institute of Biochemistry and Molecular Biology, University of Freiburg
Career Start Year 2008
Number of shared co-authors 1
Isabelle Martins
Universite de Paris, Sorbonne Universite, Inserm U8, Institut Universitaire de France
Career Start Year 2007
Number of shared co-authors 2
Young K Song
National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 1
Margret H Ogmundsdottir
Biomedical Center, University of Iceland
Career Start Year 2007
Number of shared co-authors 0
Malia B Potts
St. Jude Children's Research Hospital
Career Start Year 2004
Number of shared co-authors 1
Barak Rotblat
Ben-Gurion University of the Negev
Career Start Year 2002
Number of shared co-authors 8
Wendy Wei-Lynn Wong
Institute of Experimental Immunology, University of Zurich .
Career Start Year 2000
Number of shared co-authors 0
Hyunjoo Cha-Molstad
University of Science and Technology
Career Start Year 2000
Number of shared co-authors 0
Fan Yang
West China Second Hospital, Sichuan University
Career Start Year 2000
Number of shared co-authors 1
Rachel Toth
University of Dundee
Career Start Year 1999
Number of shared co-authors 3
Yan Liu
Chengdu Medical College
Career Start Year 1999
Number of shared co-authors 0
Chandra C Ghosh
The Wistar Institute
Career Start Year 1999
Number of shared co-authors 0
Yihong Ye
National Institute of Diabetes, National Institutes of Health
Career Start Year 1998
Number of shared co-authors 0
Rasmus Hartmann-Petersen
University of Copenhagen
Career Start Year 1998
Number of shared co-authors 0
Thorsten Berger
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1998
Number of shared co-authors 0
Yien Che Tsai
Center for Cancer Research, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 1
Ji Eun Oh
College of Science & Industry Convergence, Ewha Womans University
Career Start Year 1997
Number of shared co-authors 1
Michael C Bassik
Stanford University Medical Center
Career Start Year 1997
Number of shared co-authors 2
Arnaud Jacquel
Universite Cote d'Azur, INSERM U5
Career Start Year 1995
Number of shared co-authors 1
Scott A Oakes
Pritzker School of Medicine, University of Chicago
Career Start Year 1995
Number of shared co-authors 3
Jose Antonio Rodriguez
University of the Basque Country (UPV/EHU)
Career Start Year 1995
Number of shared co-authors 8
Dirk Geerts
Amsterdam University Medical Center
Career Start Year 1989
Number of shared co-authors 0
Ze'ev Ronai
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1981
Number of shared co-authors 8
Stanley Lipkowitz
Center for Cancer Research, National Cancer Institute
Career Start Year 1978
Number of shared co-authors 2

Collaborators

Ivan Dikic
Institute of Biochemistry II, Goethe University Frankfurt
Co-authored papers 13
Volker D??tsch
Institute for Biophysical Chemistry, Goethe-University
Co-authored papers 6
Zvulun Elazar
Weizmann Institute of Science
Co-authored papers 4
Ioannis P Nezis
University of Warwick
Co-authored papers 3
Thomas J Begley
University at Albany
Co-authored papers 2
Ramnik J Xavier
Broad Institute of MIT and Harvard
Co-authored papers 2
Christiaan Leeuwenburgh
Institute on Aging, University of Florida
Co-authored papers 2
Maria T Diaz-Meco
Co-authored papers 2
Marie-Jos??e H??bert
Universite de Montreal
Co-authored papers 2
Sovan Sarkar
CRUK MRC Oxford Institute for Radiation Oncology, University of Oxford
Co-authored papers 2
Malene Hansen
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 2
Kun-Liang Guan
University of California San Diego
Co-authored papers 2
Ana Maria Cuervo
Albert Einstein College of Medicine
Co-authored papers 2
Andreas Brech
Institute for Cancer Research, Oslo University Hospital
Co-authored papers 2
Laura Santambrogio
Weill Cornell School of Medicine
Co-authored papers 2
Scott J Bultman
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Co-authored papers 2
Masashi Narita
Co-authored papers 2
Karin Przyklenk
Co-authored papers 2
Jason E Gestwicki
Institute for Neurodegenerative Diseases, University of California San Francisco
Co-authored papers 2
Svetlana Dokudovskaya
CNRS UMR9018, Institut Gustave Roussy, Universite Paris-Saclay
Co-authored papers 2
Hirotaka Watada
Co-authored papers 2
Sara Cherry
University of Pennsylvania
Co-authored papers 2
Clare M Isacke
Co-authored papers 2
Carlos L??pez-Ot??n
Instituto Universitario de Oncologia, Universidad de Oviedo
Co-authored papers 2
David Sulzer
New York State Psychiatric Institute, Research Foundation for Mental Hygiene
Co-authored papers 2
David M Sabatini
Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology
Co-authored papers 2
J. Wade Harper
Harvard Medical School
Co-authored papers 2
Nikolai V Gorbunov
Armed Forces Radiobiology Research Institute
Co-authored papers 2
Juan Fueyo
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 2
Lawrence H Boise
Winship Cancer Institute, Emory University
Co-authored papers 2
Release 1.2